MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacc.2017.10.062

Медицинская библиотека · Journal of the American College of Cardiology · 2017

Beating-Heart Mitral Valve Repair Using a Novel ePTFE Cordal Implantation Device: A Prospective Trial.

Gammie James S, Bartus Krzysztof, Gackowski Andrzej, D'Ambra Michael N, Szymanski Piotr, Bilewska Agata, Kusmierczyk Mariusz, Kapelak Boguslaw, Rzucidlo-Resil Jolanta, Moat Neil, Duncan Alison, Yadev Rashmi, Livesey Steve, Diprose Paul, Gerosa Gino, D'Onofrio Augusto, Pitterello Demetrio, Denti Paolo, La Canna Giovanni, De Bonis Michele, Alfieri Ottavio, Hung Judy, Kolsut Piotr

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Conventional mitral valve (MV) operations allow direct anatomic assessment and repair on an arrested heart, but require cardiopulmonary bypass, aortic cross-clamping, sternotomy or thoracotomy, and cardioplegic cardiac arrest, and are associated with significant perioperative disability, and risks of morbidity and mortality.

OBJECTIVES

This study evaluated safety and performance of a transesophageal echocardiographic-guided device designed to implant artificial expanded polytetrafluoroethylene (ePTFE) cords on mitral leaflets in the beating heart.

METHODS

In a prospective multicenter study, 30 consecutive patients with severe degenerative mitral regurgitation (MR) were treated with a mitral valve repair system (MVRS) via small left thoracotomy. The primary (30-day) endpoint was successful implantation of cords with MR reduction to moderate or less.

RESULTS

The primary endpoint was met in 27 of 30 patients (90%). Three patients required conversion to open mitral surgery. There were no deaths, strokes, or permanent pacemaker implantations. At 1 month, MR was mild or less in 89% (24 of 27) and was moderate in 11% (3 of 27). At 6 months, MR was mild or less in 85 % (22 of 26), moderate in 8% (2 of 26), and severe in 8% (2 of 26). Favorable cardiac remodeling at 6 months included decreases in end-diastolic (161 ± 36 ml to 122 ± 30 ml; p < 0.001) and left atrial volumes (106 ± 36 ml to 69 ± 24 ml; p < 0.001). The anterior-posterior mitral annular dimension decreased from 34.7 ± 5.8 mm to 28.2 ± 5.1 mm; p < 0.001 as did the mitral annular area (10.0 ± 2.7 cm2 vs. 6.9 ± 2.0 cm2; p < 0.0001).

CONCLUSIONS

MVRS ePTFE cordal implantation can reduce the invasiveness and morbidity of conventional MV surgery. The device's safety profile is promising and prospective trials comparing the outcomes of the MVRS to conventional MV repair surgery are warranted. (CE Mark Study for the Harpoon Medical Device [TRACER]; NCT02768870).

Для цитирования: Gammie James S, Bartus Krzysztof, Gackowski Andrzej, D'Ambra Michael N, Szymanski Piotr, Bilewska Agata, Kusmierczyk Mariusz, Kapelak Boguslaw, Rzucidlo-Resil Jolanta, Moat Neil, Duncan Alison, Yadev Rashmi, Livesey Steve, Diprose Paul, Gerosa Gino, D'Onofrio Augusto, Pitterello Demetrio, Denti Paolo, La Canna Giovanni, De Bonis Michele, Alfieri Ottavio, Hung Judy, Kolsut Piotr. Beating-Heart Mitral Valve Repair Using a Novel ePTFE Cordal Implantation Device: A Prospective Trial.. Journal of the American College of Cardiology. 2017. DOI: 10.1016/j.jacc.2017.10.062.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.